SynthesisThe Cochrane database of systematic reviews2012
Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration.
Synthesis in The Cochrane database of systematic reviews, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 3 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- The treatment methods for post-stroke visual impairment: A systematic review.Brain and behavior · 2017Pooled it
- Fish Consumption and Age-Related Macular Degeneration Incidence: A Meta-Analysis and Systematic Review of Prospective Cohort Studies.Nutrients · 2016Pooled it
- Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration.The Cochrane database of systematic reviews · 2015Pooled it
- Role of plasma fatty acid in age-related macular degeneration: insights from a mendelian randomization analysis.Lipids in health and disease · 2024Article
- Advanced age-related macular degeneration and risk factors in eyes with pachydrusen.Scientific reports · 2024Article
- Evaluation of inflammatory hyperreflective foci and plasma EPA as diagnostic and predictive markers for age-related macular degeneration.Frontiers in neuroscience · 2024Article
- The value of nutritional supplements in treating Age-Related Macular Degeneration: a review of the literature.International ophthalmology · 2019Review
- Article
- Nutritional and Lifestyle Interventions for Age-Related Macular Degeneration: A Review.Oxidative medicine and cellular longevity · 2017Review
- Interventions for Age-Related Macular Degeneration: Are Practice Guidelines Based on Systematic Reviews?Ophthalmology · 2016Article
Corrections and comments
- Updated by
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundEvidence from animal models and observational studies in humans has suggested that there is an inverse relationship between dietary intake of omega 3 long-chain polyunsaturated fatty acids (LCPUFA) and risk of developing age-related macular degeneration (AMD) or progressing to advanced AMD.
objectivesTo review the evidence that increasing the levels of omega 3 LCPUFA in the diet (either by eating more foods rich in omega 3 or by taking nutritional supplements) prevents AMD or slows the progression of AMD. SEARCH
methodsWe searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2012, Issue 4), MEDLINE (January 1950 to April 2012), EMBASE (January 1980 to April 2012), Latin American and Caribbean Literature on Health Sciences (LILACS) (January 1982 to April 2012), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. The electronic databases were last searched on 26 April 2012. SELECTION CRITERIA: We planned to include randomised controlled trials (RCTs) where increased dietary intake of omega 3 fatty acids was compared to placebo or no intervention with the aim of preventing the development of AMD, or slowing its progression. DATA COLLECTION AND ANALYSIS: Both authors independently screened titles, abstracts and full-texts of articles to identify studies for inclusion and analysis. MAIN
resultsNo trials met the selection criteria. The results of a large, multi-centre, randomised trial (AREDS2) that will assess the effects of oral supplementation with omega 3 LCPUFA on progression to advanced AMD are expected in 2013. Two further trials are also ongoing. AUTHORS'
conclusionsUntil data from RCTs become available for analysis, there is currently no evidence to support increasing levels of omega 3 LCPUFA in the diet for the explicit purpose of preventing or slowing the progression of AMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.